Market Place
Sourcing Support
Synthekine`s Ph 1 Data for CD19 CAR-T & IL-2 Therapy at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
Synthekine Presents STK-012 IL-2 Data at 39th SITC 2024
08 Nov 2024 //
BUSINESSWIRE
Synthekine Granted FDA Fast Track for CD19 CAR-T Therapy SYNCAR-001 + STK-009
04 Sep 2024 //
BUSINESSWIRE
Synthekine Reports Positive Results from STK-012 Trial
09 Apr 2024 //
BUSINESSWIRE
Synthekine Announces IND Clearance for CD19 CAR-T and Ortho IL-2, SYNCAR-001
26 Mar 2024 //
BUSINESSWIRE
Synthekine Announces Presentation of Results from Phase 1a/1b Trial of STK-012
07 Mar 2024 //
BUSINESSWIRE
Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer
21 Feb 2024 //
BUSINESSWIRE
Synthekine Announces Strategic Collaboration with Sanofi
29 Jan 2024 //
BUSINESSWIRE
Synthekine Presents Data Demonstrating its IL-12 Partial Agonist
03 Nov 2023 //
BUSINESSWIRE
First Patient Dosed in Phase 1b Trial of Synthekine’s ?/? Biased IL-2, STK-012
28 Sep 2023 //
BUSINESSWIRE
Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2
27 Jul 2023 //
BUSINESSWIRE
Synthekine Announces Presentations at AACR Showcasing Next Series of Oncology Programs
12 Apr 2023 //
BUSINESSWIRE
Synthekine Secures $100 M Series C Financing of Engineered Cytokine Therapeutics
06 Jan 2023 //
BUSINESSWIRE
Synthekine Announces Multiple Poster Ppts on Cytokine Engineering Platforms
07 Apr 2022 //
BUSINESSWIRE
Synthekine Doses First Patient in Phase 1 Clinical Trial of STK-012
03 Feb 2022 //
BUSINESSWIRE
Synthekine Publishes PC Data on In Vivo Control of CD19 CAR-T Cells
23 Dec 2021 //
BUSINESSWIRE
Synthekine Publishes PC Data on In Vivo Control of CD19 CAR-T Cells
23 Dec 2021 //
BUSINESSWIRE
Merck inks $525M biobucks pact for Synthekine`s cytokine target
02 Nov 2021 //
FIERCEBIOTECH
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation
28 Oct 2021 //
BIOSPACE
Synthekine Announces $107.5 Million Oversubscribed Series B Financing
10 Jun 2021 //
BUSINESSWIRE
Synthekine Announces $107.5 Million Oversubscribed Series B Financing
10 Jun 2021 //
BUSINESSWIRE
Synthekine Appoints Naiyer Rizvi, M.D., as Chief Medical Officer
03 May 2021 //
BUSINESSWIRE
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating IL-2
09 Apr 2021 //
BUSINESSWIRE
Synthekine Presents Data at American Society of Hematology Annual Showing
07 Dec 2020 //
BUSINESSWIRE
Synthekine Data at American Society of ASH Showing Orthogonal IL-2 Ligand
07 Dec 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.